-
Something wrong with this record ?
Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy
M. Dolezel, K. Odrazka, M. Vaculikova, J. Vanasek, J. Sefrova, P. Paluska, M. Zouhar, J. Jansa, Z. Macingova, L. Jarosova, M. Brodak, P. Moravek, I. Hartmann
Language English Country Germany
Document type Comparative Study, Journal Article
NLK
ProQuest Central
from 1997-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2006-08-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 1997-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 1997-01-01 to 1 year ago
Public Health Database (ProQuest)
from 1997-01-01 to 1 year ago
- MeSH
- Acute Disease MeSH
- Dose Fractionation, Radiation MeSH
- Gastrointestinal Diseases epidemiology etiology MeSH
- Gastrointestinal Tract radiation effects MeSH
- Incidence MeSH
- Combined Modality Therapy MeSH
- Radiotherapy, Conformal adverse effects methods MeSH
- Middle Aged MeSH
- Humans MeSH
- Male Urogenital Diseases epidemiology etiology MeSH
- Prostatic Neoplasms pathology radiotherapy MeSH
- Follow-Up Studies MeSH
- Prospective Studies MeSH
- Prostate radiation effects MeSH
- Cross-Sectional Studies MeSH
- Radiation Injuries epidemiology etiology MeSH
- Radiotherapy, Intensity-Modulated methods MeSH
- Risk Factors MeSH
- Seminal Vesicles radiation effects MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Neoplasm Staging MeSH
- Urogenital System radiation effects MeSH
- Dose-Response Relationship, Radiation MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Comparative Study MeSH
PURPOSE: To compare acute and late toxicity after three-dimensional conformal radiotherapy to the prostate to 74 Gy (3D-CRT) with intensity-modulated radiotherapy to 78 Gy (IMRT 78) and IMRT using simultaneous integrated boost to 82 Gy (IMRT/SIB 82). PATIENTS AND METHODS: 94 patients treated with 3D-CRT to the prostate and base of seminal vesicles to 74 Gy represented the first group. The second group consisted of 138 patients subjected to IMRT covering the prostate and base of seminal vesicles to 78 Gy. The last group was treated with IMRT using SIB. The prescribed doses were 82 Gy and 73.8 Gy in 42 fractions to the prostate and seminal vesicles. Late toxicity was prospectively scored according to the RTOG/FC-LENT scale. RESULTS: Acute gastrointestinal toxicity >or= grade 2 occurred in 35.1% of patients treated with 3D-CRT, in 16% subjected to IMRT 78, and in 7.7% receiving IMRT/SIB 82. Acute genitourinary toxicity >or= grade 2 was observed in 26.6% (3D-CRT), 33% (IMRT 78), and 30.7% (IMRT/SIB 82). At 3 years, the estimated cumulative incidence of grade 3 late gastrointestinal toxicity was 14% for 3D-CRT, 5% for IMRT 78, and 2% for IMRT/SIB 82. The difference became significant (log rank p = 0.02). The estimated cumulative incidence of grade 3 late genitourinary toxicity was 9% (3D-CRT), 7% (IMRT 78), and 6% (IMRT/SIB 82) without statistical differences (log rank p = 0.32) CONCLUSION: SIB enables dose escalation up to 82 Gy with a lower rate of gastrointestinal toxicity grade 3 in comparison with 3D-CRT up to 74 Gy.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12025102
- 003
- CZ-PrNML
- 005
- 20130124192837.0
- 007
- ta
- 008
- 120816e20100326gw f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00066-010-2065-x $2 doi
- 035 __
- $a (PubMed)20354663
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Doležel, Martin $7 xx0075943 $u Oncology Center, Multiscan & Pardubice Regional Hospital, Pardubice, Czech Republic. dolezelm@email.cz
- 245 10
- $a Dose escalation in prostate radiotherapy up to 82 Gy using simultaneous integrated boost: direct comparison of acute and late toxicity with 3D-CRT 74 Gy and IMRT 78 Gy / $c M. Dolezel, K. Odrazka, M. Vaculikova, J. Vanasek, J. Sefrova, P. Paluska, M. Zouhar, J. Jansa, Z. Macingova, L. Jarosova, M. Brodak, P. Moravek, I. Hartmann
- 520 9_
- $a PURPOSE: To compare acute and late toxicity after three-dimensional conformal radiotherapy to the prostate to 74 Gy (3D-CRT) with intensity-modulated radiotherapy to 78 Gy (IMRT 78) and IMRT using simultaneous integrated boost to 82 Gy (IMRT/SIB 82). PATIENTS AND METHODS: 94 patients treated with 3D-CRT to the prostate and base of seminal vesicles to 74 Gy represented the first group. The second group consisted of 138 patients subjected to IMRT covering the prostate and base of seminal vesicles to 78 Gy. The last group was treated with IMRT using SIB. The prescribed doses were 82 Gy and 73.8 Gy in 42 fractions to the prostate and seminal vesicles. Late toxicity was prospectively scored according to the RTOG/FC-LENT scale. RESULTS: Acute gastrointestinal toxicity >or= grade 2 occurred in 35.1% of patients treated with 3D-CRT, in 16% subjected to IMRT 78, and in 7.7% receiving IMRT/SIB 82. Acute genitourinary toxicity >or= grade 2 was observed in 26.6% (3D-CRT), 33% (IMRT 78), and 30.7% (IMRT/SIB 82). At 3 years, the estimated cumulative incidence of grade 3 late gastrointestinal toxicity was 14% for 3D-CRT, 5% for IMRT 78, and 2% for IMRT/SIB 82. The difference became significant (log rank p = 0.02). The estimated cumulative incidence of grade 3 late genitourinary toxicity was 9% (3D-CRT), 7% (IMRT 78), and 6% (IMRT/SIB 82) without statistical differences (log rank p = 0.32) CONCLUSION: SIB enables dose escalation up to 82 Gy with a lower rate of gastrointestinal toxicity grade 3 in comparison with 3D-CRT up to 74 Gy.
- 650 _2
- $a akutní nemoc $7 D000208
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a průřezové studie $7 D003430
- 650 _2
- $a frakcionace dávky záření $7 D019583
- 650 _2
- $a vztah dávky záření a odpovědi $7 D004307
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a gastrointestinální nemoci $x epidemiologie $x etiologie $7 D005767
- 650 _2
- $a gastrointestinální trakt $x účinky záření $7 D041981
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mužské urogenitální nemoci $x epidemiologie $x etiologie $7 D052801
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a prostata $x účinky záření $7 D011467
- 650 _2
- $a nádory prostaty $x patologie $x radioterapie $7 D011471
- 650 _2
- $a radiační poranění $x epidemiologie $x etiologie $7 D011832
- 650 _2
- $a konformní radioterapie $x škodlivé účinky $x metody $7 D020266
- 650 _2
- $a radioterapie s modulovanou intenzitou $x metody $7 D050397
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a semenné váčky $x účinky záření $7 D012669
- 650 _2
- $a urogenitální systém $x účinky záření $7 D014566
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Odrážka, Karel $7 mzk2002148290
- 700 1_
- $a Vaculíková, Miloslava $7 xx0070864
- 700 1_
- $a Vaňásek, Jaroslav, $d 1952- $7 nlk19990073982
- 700 1_
- $a Šefrová, Jana $7 xx0135654
- 700 1_
- $a Paluska, Petr $7 xx0135658
- 700 1_
- $a Zouhar, Milan $7 xx0135657
- 700 1_
- $a Jansa, Jan $7 xx0103093
- 700 1_
- $a Mačingová, Zuzana $7 xx0093749
- 700 1_
- $a Jarošová, Lída
- 700 1_
- $a Broďák, Miloš, $d 1968- $7 xx0079082
- 700 1_
- $a Morávek, Petr, $d 1942- $7 jn99240000736
- 700 1_
- $a Hartmann, Igor $7 xx0064383
- 773 0_
- $w MED00010658 $t Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al] $x 1439-099X $g Roč. 186, č. 4 (20100326), s. 197-202
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20354663 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120816 $b ABA008
- 991 __
- $a 20130124193006 $b ABA008
- 999 __
- $a ok $b bmc $g 947144 $s 782448
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 186 $c 4 $d 197-202 $e 20100326 $i 1439-099X $m Strahlentherapie und Onkologie $n Strahlenther Onkol $x MED00010658
- LZP __
- $a Pubmed-20120816/10/02